Section Arrow
FENC.NASDAQ
- Fennec Pharmaceuticals
Quotes are at least 15-min delayed:2026/04/10 15:55 EDT
After Hours
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 5.83
-0.57 (-8.91%)
Day High 
6.44 
Prev. Close
6.4 
1-M High
8.34 
Volume 
263.55K 
Bid
5.83
Ask
5.84
Day Low
5.81 
Open
6.39 
1-M Low
5.65 
Market Cap 
220.64M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 6.28 
20-SMA 6.78 
50-SMA 7.6 
52-W High 9.92 
52-W Low 4.98 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.34/1.32
Enterprise Value
239.98M
Balance Sheet
Book Value Per Share
1.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
44.64M
Operating Revenue Per Share
0.19
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.4784+0.1855+63.33%-- 
After Hours -- -- --
QNCXQuince Therapeutics0.1304+0.0067+5.42%-- 
After Hours -- -- --
ZNTLZentalis Pharmaceuticals6.72+2.3+52.04%-- 
After Hours -- -- --
IOVAIovance Biotherapeutics3.67-0.34-8.48%-- 
After Hours -- -- --
GERNGeron Corp1.685-0.075-4.26%-- 
After Hours -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.